Guest Editors
Zhijia Xia, Department of General, Visceral, and Transplant Surgery, Ludwig-Maximilians University Munich, Munich, Germany.
Email: zhijia_xia@yeah.net
Dingwei Ye, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Email: dwyelie@163.com
Zhendong Jin, Department of Gastroenterology, Digestive Endoscopy Center, Changhai Hospital, Shanghai, China.
Email: zhendongjin@163.com
Bo Zhai, Department of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Email: zhaiboshi@sina.com
Jing Zhang, Division of Basic Biomedical Sciences, The University of South Dakota Sanford School of Medicine, Vermillion, South Dakota, USA. Email: jing.zhang@coyotes.usd.edu
Summary
As technology continues to advance and medical research progresses, methods for diagnosing, treating, and assessing the prognosis of solid tumors are constantly updated and improved. Radiation therapy and chemotherapy are common methods for treating tumors by using high-energy radiation or drugs to control or eliminate tumor cells. Immunotherapy is a method of treating tumors by utilizing the power of the body's immune system. Some new biomarkers have been discovered that can predict the sensitivity and tolerability of tumors to radiation therapy, chemotherapy, and immunotherapy. In addition, the types and quantities of immune cells in the tumor microenvironment can also predict the effectiveness of immunotherapy. These biomarkers can be used to select appropriate patients for radiation therapy, chemotherapy, and immunotherapy, to improve treatment efficacy and reduce adverse reactions.
In addition to these biomarkers and treatment methods, there are also some new technologies being used for the diagnosis, treatment, and prognosis of solid tumors. For example, biological markers such as circulating tumor DNA (ctDNA) and microRNAs (miRNAs) have been used for early diagnosis and prognosis assessment of solid tumors. At the same time, the application of technologies such as artificial intelligence and machine learning has also provided new ideas and methods for solid tumor treatment.
This special issue focuses on novel solid tumor biomarkers and treatment strategies, including radiation therapy, chemotherapy, targeted therapy, and immunotherapy. We welcome the submission of original research and review articles, including basic and clinical research.
Potential topics include but are not limited to the following:
1. Emerging biomarkers for the prediction of immunotherapy and chemotherapy adverse events
2. Novel diagnostic and prognostic biomarkers for solid tumors.
3. Artificial intelligence (AI) -driven therapeutics: Innovations in cancer management
4. Recent advances in the field of novel chemotherapeutic agents, including nanotechnology and targeted therapeutics.
5. The association between the immune microenvironment and cancer development.
6. Utilization of circulating tumor DNA and microRNA for the diagnosis and prognostic evaluation of solid tumors.
7. Exploration of factors influencing tumor progression through mendelian randomization analysis.
Keywords
Biomarker, Artificial Intelligence (AI), treatment strategy, immune, solid tumor
Published Papers
Login
Register
Submit a Paper
Propose a Special lssue